Maiara Camotti Montanha

Maiara Camotti Montanha

Auto-generated profile, based on publicly available information

Maiara Camotti Montanha

University of Liverpool

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2017 in Journal of Photochemistry and Photobiology B: Biology
Verified
Journal Article
Closed access
MMMaiara Camotti Montanha
Maiara Camotti Montanha
LSLarissa Lachi Silva
Larissa Lachi Silva
FPFernanda Belincanta Borghi Pangoni
Fernanda Belincanta Borghi Pangoni
GCGabriel Batista Cesar
Gabriel Batista Cesar
RGRenato Sonchini Gonçalves
Renato Sonchini Gonçalves
EKElza Kimura
Elza Kimura

10 February 2024 in British Journal of Clinical Pharmacology
Verified
Journal Article
Open access
SAShakir Atoyebi
Shakir Atoyebi
FBFazila Bunglawala
Fazila Bunglawala
NCNicolas Cottura
Nicolas Cottura
SGSandra Grañana‐Castillo
Sandra Grañana‐Castillo
MMMaiara Camotti Montanha
Maiara Camotti Montanha
CWCatriona Waitt
Catriona Waitt
Aims: Long‐acting cabotegravir and rilpivirine have been approved to manage HIV in adults, but data regarding safe use in pregnancy are limited. Physiologically‐based pharmacokinetic (PBPK) modelling was used to simulate the approved dosing regimens in pregnancy and explore if Ctrough was maintained above cabotegravir and rilpivirine target concentrations (664 and 50 ng/mL, respectively).Methods: An adult PBPK model was validated using clinical data of cabotegravir and rilpivirine in nonpregnant adults. This was modified by incorporating pregnancy‐induced metabolic and physiological changes. The pregnancy PBPK model was validated with data on oral rilpivirine and raltegravir (UGT1A1 probe substrate) in pregnancy. Twelve weeks' disposition of monthly and bimonthly dosing of long‐acting cabotegravir and rilpivirine was simulated at different trimesters and foetal exposure was also estimated.Results: Predicted Ctrough at week 12 for monthly long‐acting cabotegravir was above 664 ng/mL throughout pregnancy, but below the target in 0.5% of the pregnant population in the third trimester with bimonthly long‐acting cabotegravir. Predicted Ctrough at week 12 for monthly and bimonthly long‐acting rilpivirine was below 50 ng/mL in at least 40% and over 90% of the pregnant population, respectively, throughout pregnancy. Predicted medians (range) of cord‐to‐maternal blood ratios were 1.71 (range, 1.55‐1.79) for cabotegravir and 0.88 (0.78‐0.93) for rilpivirine between weeks 38 and 40.Conclusions: Model predictions suggest that monthly long‐acting cabotegravir could maintain antiviral efficacy throughout pregnancy, but that bimonthly administration may require careful clinical evaluation. Both monthly and bimonthly long‐acting rilpivirine may not adequately maintain antiviral efficacy in pregnancy.

20 January 2021 in British Journal of Clinical Pharmacology
Verified
Journal Article
Closed access
PDF file
ASAna Luiza P.P.D.P. Soares
Ana Luiza P.P.D.P. Soares
MMMaiara C. Montanha
Maiara C. Montanha
CAConrado D.S. Alcantara
Conrado D.S. Alcantara
SSSandra R.B. Silva
Sandra R.B. Silva
CKCristina M. Kuroda
Cristina M. Kuroda
EKElza Kimura
Elza Kimura

1 February 2021 in Journal of Photochemistry and Photobiology A: Chemistry
Verified
Journal Article
Closed access
AOAngélica Gonçalves Oliveira
Angélica Gonçalves Oliveira
JAJéssica de Lara Andrade
Jéssica de Lara Andrade
MMMaiara Camotti Montanha
Maiara Camotti Montanha
COCamilla Yara Langer Ogawa
Camilla Yara Langer Ogawa
TFThábata Karoliny Formicoli de Souza Freitas
Thábata Karoliny Formicoli de Souza Freitas
DODaniela Martins Fernandes de Oliveira
Daniela Martins Fernandes de Oliveira

12 July 2019 in British Journal of Clinical Pharmacology
Verified
Journal Article
Closed access
MMMaiara Camotti Montanha
Maiara Camotti Montanha
TMThiago Ferreira dos Santos Magon
Thiago Ferreira dos Santos Magon
CAConrado de Souza Alcantara
Conrado de Souza Alcantara
CSCaroline Ferraz Simões
Caroline Ferraz Simões
SSSandra Regina Bin Silva
Sandra Regina Bin Silva
EKElza Kimura
Elza Kimura

13 May 2022 in Drug Delivery and Translational Research
Verified
Journal Article
Closed access
PDF file
MMMaiara Camotti Montanha
Maiara Camotti Montanha
AHAlice Howarth
Alice Howarth
DMDoaa Ahmed Mohamed
Doaa Ahmed Mohamed
ELEstelle Loier
Estelle Loier
LMLauren Main
Lauren Main
MSMarco Siccardi
Marco Siccardi